EUVIMEDEUVIMED entdecken
Crossref

Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis

Riko Ikeda iD, Soichiro Yoshida iD, Wei Chen, Motohiro Fujiwara iD, Shugo Yajima iD, Hiroshi Fukushima iD, Yosuke Yasuda, Hajime Tanaka iD, Hiroyuki Sato iD, Akihiro Hirakawa iD, Yasuhisa Fujii iD

International Journal of Urology · 2026-10 · 33 (10)

DOI: 10.1111/iju.70667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 07.10.2026. Verfasst von Riko Ikeda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Urinary Bladder Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Perioperative treatment with enfortumab vedotin (EV) plus pembrolizumab has demonstrated a high pathological complete response (pCR) rate in patients with cisplatin‐ineligible muscle‐invasive bladder cancer (MIBC). However, whether this therapeutic benefit reflects true pharmacologic synergy or can be explained by independent drug action (IDA) remains uncertain.

Methods

We analyzed data from EV‐103 cohort H (EV monotherapy), the cisplatin‐ineligible subset of PURE‐01 (pembrolizumab monotherapy), and KEYNOTE‐905/EV‐303 (EV plus pembrolizumab). An IDA model incorporating a Gaussian copula was applied to estimate the predicted pCR rate of the combination therapy. The primary analysis assumed weak positive dependence between drug responses (correlation coefficient ρ = 0.24). Sensitivity analyses evaluated the observed‐minus‐IDA‐predicted pCR difference across a continuous range of dependence assumptions ( ρ = 0.00–0.99).

Results

The predicted pCR rate for EV plus pembrolizumab was 53.5%, consisting of 21.4% EV‐only responders, 17.1% pembrolizumab‐only responders, and 15.0% dual responders. The observed pCR rate in the KEYNOTE‐905/EV‐303 trial was 57.1%, corresponding to an absolute difference of 3.6 percentage points compared with the model prediction. In sensitivity analyses, the posterior median observed‐minus‐predicted difference increased with stronger positive dependence, but the 95% credible intervals were wide and included zero across a broad range of dependence assumptions.

Conclusions

Although modest pharmacologic synergy cannot be excluded given the uncertainty in the available data, substantial population‐level pharmacologic synergy is not required to explain the high pCR observed with the combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedUrinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansPathologic Complete ResponseNeoadjuvant TherapyFemaleDrug SynergismMaleNeoplasm InvasivenessAgedAntineoplastic Agents, ImmunologicalCystectomy

Stichwörter der Autor:innen

bladder cancercopula modelenfortumab vedotinindependent drug actionpembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan, China.
  • Department of Urology, Teikyo University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan.
  • Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Riko Ikeda, Soichiro Yoshida, Motohiro Fujiwara, Shugo Yajima, Hiroshi Fukushima, Hajime Tanaka, Hiroyuki Sato, Akihiro Hirakawa, Yasuhisa Fujii

Zitieren

APA

Ikeda, R., Yoshida, S., Chen, W., Fujiwara, M., Yajima, S., Fukushima, H., Yasuda, Y., Tanaka, H., Sato, H., Hirakawa, A., & Fujii, Y. (2026). Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis. International Journal of Urology, 33(10). https://doi.org/10.1111/iju.70667

Vancouver

Ikeda R, Yoshida S, Chen W, Fujiwara M, Yajima S, Fukushima H, et al. Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis. International Journal of Urology. 2026;33(10). doi:10.1111/iju.70667

BibTeX
@article{Ikeda2026,
  author = {Ikeda, Riko and Yoshida, Soichiro and Chen, Wei and Fujiwara, Motohiro and Yajima, Shugo and Fukushima, Hiroshi and Yasuda, Yosuke and Tanaka, Hajime and Sato, Hiroyuki and Hirakawa, Akihiro and Fujii, Yasuhisa},
  title = {Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle‐Invasive Bladder Cancer: A Copula‐Based Secondary Analysis},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {10},
  doi = {10.1111/iju.70667}
}
Kostenlos starten →